EU revises GMP guide on products derived from human blood, plasma
This article was originally published in RAJ Devices
The European Commission has substantially revised its guidance on good manufacturing practice requirements for drugs derived from human blood or plasma that is fractionated in, or imported into, the EU/European Economic Area1,2. The updated guidance also applies to stable derivatives of human blood or human plasma (eg albumin) incorporated into medical devices.
You may also be interested in...
The risk of psychiatric disorders with chloroquine and hydroxychloroquine-containing medicines received renewed attention in the EU after they were being used as potential treatments for COVID-19.
New UK guidance explains how clinical trial sponsors and investigator sites can ensure that trial monitors securely process data in electronic health record systems that do not have a restricted access functionality.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.